Stopping Ozempic, Wegovy, or Zepbound is not the end of the story - it is often the start of a frustrating new chapter. Research consistently shows that most of the weight comes back. Fast. But 2026 has brought the clearest picture yet of what might actually help.

The scale of the problem

Around 70% of people on GLP-1 medications discontinue within the first year. The reasons vary - cost, side effects, access issues, or simply not wanting to inject indefinitely. What happens next is well documented: the majority regain all of the weight they lost within approximately 18 months of stopping.

This is not a willpower problem. GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work by suppressing appetite signals in the brain and gut. When you stop the medication, those signals return - often stronger than before, as if the body is trying to recover lost tissue. The set-point theory of body weight is real, and it is aggressive in the rebound phase.

One analysis projected a 0.4 kg per month regain trajectory after discontinuation, with most patients returning to their pre-treatment weight within roughly 1.7 years. For someone who spent months losing 20 or 30 kg, that number lands hard.

Two procedures making headlines at DDW 2026

The 2026 Digestive Disease Week conference (DDW) - the largest international gathering in gastroenterology - presented the most compelling new data on post-GLP-1 rebound prevention. Two procedures attracted particular attention.

Endoscopic sleeve gastroplasty (ESG)

ESG is a non-surgical procedure that reduces stomach volume by approximately 70% using an endoscope and suture device. It physically restructures the stomach without removing tissue, which distinguishes it from surgical sleeve gastrectomy.

At DDW 2026, a comparative study examined three groups of patients who had stopped GLP-1 therapy:

  • ESG group (n = 42): achieved 17.9% total body weight loss
  • Switching from semaglutide to tirzepatide (n = 35): 5% total weight loss
  • Lifestyle modification alone (n = 26): 0.8% total weight loss

The gap between ESG and lifestyle-alone is stark. For patients who cannot stay on GLP-1 medications long-term, an endoscopic procedure that maintains weight loss at nearly 18% represents a meaningful option - though it comes with its own cost, recovery, and access considerations.

Duodenal mucosal resurfacing (DMR)

DMR is newer and still investigational. The procedure uses targeted heat (hydrothermal ablation) to remove the inner mucosal lining of the duodenum - the first section of the small intestine just below the stomach. The duodenum is where many of the gut hormones involved in metabolism, including GLP-1, are produced and sensed. High-fat, high-sugar diets over years thicken and damage this lining, effectively rewiring how your gut responds to food.

DMR ablates that damaged layer and stimulates regrowth of healthy tissue - essentially a metabolic reset of the duodenum.

The REMAIN-1 trial, presented at DDW 2026 by Dr. Shelby Sullivan of Dartmouth Health Weight Center, provided the first blinded, randomised, sham-controlled evidence for DMR in post-GLP-1 patients. At midpoint analysis (45 participants; 29 received DMR, 16 received a sham procedure):

  • All participants had lost at least 15% body weight on tirzepatide before discontinuation - roughly 40 pounds on average
  • Six months after stopping GLP-1 therapy, the sham group regained 40% more weight than the DMR group
  • Patients who received longer resurfacing (more tissue ablated) regained only about 7 pounds, maintaining over 80% of their weight loss
  • The sham group regained roughly double that amount
  • No serious complications were reported
  • Recovery time was minimal - most patients returned to normal activities within one day

Sullivan noted something important about the DMR results: "The benefit appears to increase over time rather than fade, and behaves like a drug in dose response, giving us confidence we're targeting the right biology." That dose-response relationship - more resurfacing producing more protection - is the kind of mechanistic signal that supports the procedure's biological plausibility rather than a statistical artefact.

The full REMAIN-1 trial enrolled over 300 participants. Topline six-month pivotal cohort data is expected in Q4 2026, with a marketing submission to the FDA planned later this year.

Why these findings matter now

Both procedures address a fundamental question that GLP-1 medications leave unanswered: what happens to the metabolic changes achieved during treatment once the drug is gone?

GLP-1 medications are effective while you take them. The data from STEP-1 and SURMOUNT-1 trials is unambiguous on that. But they do not appear to durably reset the biological set-point in most people. When the drug leaves, the set-point pulls the body back toward its pre-treatment weight.

ESG addresses this mechanically - a physically smaller stomach means smaller meals trigger fullness faster, independent of any hormonal signal. DMR addresses it metabolically - by resetting the duodenal tissue that mediates gut hormone production, the procedure may create a lasting change in how your gut processes food signals.

Neither is a casual option. ESG requires an endoscopic procedure with general sedation. DMR is not yet FDA-approved. Both cost money and require access to specialised centres. But for people who achieved significant weight loss on GLP-1 medications and are now facing the rebound, these are the most credible emerging alternatives to restarting medication indefinitely.

What you can do before procedures are needed

Most people stopping GLP-1 therapy are not immediately planning an endoscopic procedure. For the majority, the realistic focus is on lifestyle and nutritional strategies that slow the rebound and preserve as much of the achieved weight loss as possible.

The evidence base here is less dramatic but more accessible:

  • Protein intake is non-negotiable. GLP-1 medications often drive significant muscle loss alongside fat loss - estimates suggest 25-40% of total weight lost can be lean mass. After stopping, prioritising protein (1.2-1.6 g/kg body weight daily) helps maintain the muscle you kept and supports satiety without the hormonal assistance of the drug.
  • Fibre slows gastric emptying. Soluble fibre from oats, legumes, and vegetables slows the rate at which food leaves your stomach, partially mimicking one mechanism of GLP-1 action on appetite. It is not a replacement, but it is meaningful.
  • Nutrient deficiencies compound the difficulty. People on GLP-1 medications commonly develop deficiencies in vitamin B12, vitamin D, iron, and magnesium - partly due to reduced food intake and partly due to changes in gastric acid production. Entering the post-GLP-1 phase already depleted makes the metabolic challenge harder. Screening and correcting these deficiencies before stopping medication is worth discussing with your doctor.
  • Resistance training is the most protective exercise modality. Cardiovascular exercise burns calories during the session. Resistance training builds metabolic tissue that burns calories at rest - which matters most during the rebound phase when hunger is elevated and the temptation to reduce activity is high.

The team at GLP-1 Shield has built a supplement formulation designed specifically for people on and transitioning off GLP-1 medications, focusing on the nutrient gaps most likely to undermine long-term maintenance.

The bigger picture

The weight regain problem after GLP-1 discontinuation is not a flaw in the patients - it is a feature of how human metabolism works. The body defends its stored energy with remarkable persistence. GLP-1 medications work powerfully against that defence while you take them. The research presented at DDW 2026 is an honest acknowledgement that stopping the drug without a plan is almost always a losing strategy - and the first serious clinical evidence that there may be structural interventions, not just behavioural ones, that can hold the line.

Worried about your own nutrient gaps on GLP-1?

Be among the first to try the scientifically designed GLP-1 Shield supplements.

Frequently asked questions

How much weight do people regain after stopping Ozempic or Wegovy?
Most studies show the majority of lost weight returns within 12-18 months of stopping GLP-1 medications. One analysis projected an average regain rate of approximately 0.4 kg per month post-discontinuation, with most patients returning close to their pre-treatment weight within about 1.7 years.
What is duodenal mucosal resurfacing and does it prevent weight regain?
Duodenal mucosal resurfacing (DMR) is an investigational endoscopic procedure that uses heat to ablate the damaged inner lining of the duodenum, stimulating regrowth of healthy metabolic tissue. The REMAIN-1 trial (midpoint data, DDW 2026) showed DMR recipients maintained over 80% of their weight loss six months after stopping tirzepatide, regaining roughly half the weight of control patients. It is not yet FDA-approved.
What is endoscopic sleeve gastroplasty and how does it compare to GLP-1 drugs?
Endoscopic sleeve gastroplasty (ESG) uses sutures delivered through an endoscope to reduce stomach volume by about 70%. At DDW 2026, post-GLP-1 patients who received ESG achieved 17.9% total weight loss, compared to just 0.8% for those relying on lifestyle changes alone after stopping their medication.
What supplements should I take after stopping GLP-1 medications?
Key nutrients to prioritise after discontinuing GLP-1 therapy include vitamin B12, vitamin D, iron, magnesium, and adequate protein. GLP-1 medications reduce food intake substantially, which can deplete these nutrients over time. Correcting these gaps before stopping medication - and maintaining them after - supports both metabolic health and energy during the weight maintenance phase.